Healthcare & Life Sciences

Seneca Therapeutics, Inc

aliveseries-b
series-b
Stage
1
Investors

About

Seneca Therapeutics develops oncolytic immunotherapeutic candidates, including Seneca Valley Virus (SVV-001), that selectively target and treat solid tumors by replicating in tumor cells expressing the TEM8 receptor.

Explore Seneca Therapeutics, Inc's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.